
Lakefront Biotherapeutics: shareholders and insiders
Price
$33.31
November 20, 2026Market cap $2.2B
What Ploutos Investor adds for Lakefront Biotherapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 11 fiscal years, from 2015
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Sorry, we do not have enough data
for purchases and sales by Lakefront Biotherapeutics's insiders
Why?
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Gilead Sciences, Inc.with 1 more personShare of class29.9%
- EcoR1 Capital, LLCwith 3 more personsShare of class13.2%
- Tang Capital Managementwith 5 more personsShare of class8.40%
- Madison Avenue International LPwith 5 more personsShare of class5.50%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Gilead Sciences, Inc.with 1 more person | 29.9% | 20.98M | Jan 10, 2025 | 13D/A | |
| EcoR1 Capital, LLCwith 3 more persons | 13.2% | 8.71M | Jul 28, 20252 filings since May 19, 2025 | 13D/A | |
| Tang Capital Managementwith 5 more persons | 8.40% | 5.56M | Oct 29, 20252 filings since Feb 14, 2025 | 13G | |
| Madison Avenue International LPwith 5 more persons | 5.50% | 3.61M | Jun 23, 2026 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Gilead Sciences, Inc.29.9%From the filing of Jan 10, 2025
Item 4 is hereby amended and supplemented with the addition of the following: Separation Agreement On January 7, 2025, the Issuer and the Reporting Persons entered into the Separation Agreement, pursuant to which and subject to the terms and conditions set forth therein, the Issuer shall separate certain assets and liabilities into a new entity ("SpinCo") through a partial demerger in the sense of Article 12:8, 1deg of the Belgian Companies and Associations Code ("een met splitsinggelijkgesteldeverrichting / uneoperationassimilee a la scission"), following which the existing shareholders of the Issuer shall receive shares in SpinCo in the same proportion as their respective shareholdings…
From the filing of Jan 10, 2025
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Greenlight / DME (Einhorn)In the quarter
- Renaissance TechnologiesIn the quarter+4.1%
- Point72 (Cohen)In the quarter-14%
- Citadel Advisors (Griffin)In the quarter+254%
- D.E. ShawIn the quarter+65%
- Millennium Mgmt (Englander)In the quarter-90%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Greenlight / DME (Einhorn) | 482.7K | $14M | 0.40% | |
| Renaissance Technologies | 424.7K | +4.1% | $13M | 0.02% |
| Point72 (Cohen) | 232.8K | -14% | $6.9M | 0.01% |
| Citadel Advisors (Griffin) | 312.6K | +254% | $9.3M | 0.01% |
| D.E. Shaw | 325.7K | +65% | $9.7M | 0.01% |
| Millennium Mgmt (Englander) | 17.6K | -90% | $500.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short sales in daily trading
How much of the shares that changed hands were short sales, in the off-exchange trades brokers report each day.
In the last 14 sessions, 57.2% of the shares in the reported trades were short sales, against 54.9% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 57.2%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 54.9%
- Change
- +2.3 pts
- Short sales a dayon average, of 99.3K shares
- 56.8K
- More than atof 3,666 US-listed companies, same days
- 75%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 44.4%
- Oct 15, 2026: Short sales 56.4%
- Oct 16, 2026: Short sales 81.7%
- Oct 19, 2026: Short sales 79.3%
- Oct 20, 2026: Short sales 36.8%
- Oct 21, 2026: Short sales 70.2%
- Oct 22, 2026: Short sales 53.6%
- Oct 23, 2026: Short sales 34.9%
- Oct 26, 2026: Short sales 58.5%
- Oct 27, 2026: Short sales 55.8%
- Oct 28, 2026: Short sales 61.8%
- Oct 29, 2026: Short sales 51%
- Oct 30, 2026: Short sales 46.1%
- Nov 2, 2026: Short sales 62.3%
- Nov 3, 2026: Short sales 63.2%
- Nov 4, 2026: Short sales 67.2%
- Nov 5, 2026: Short sales 75.4%
- Nov 6, 2026: Short sales 54.7%
- Nov 9, 2026: Short sales 28.9%
- Nov 10, 2026: Short sales 69.8%
- Nov 11, 2026: Short sales 70.6%
- Nov 12, 2026: Short sales 67.2%
- Nov 13, 2026: Short sales 74.6%
- Nov 16, 2026: Short sales 25.9%
- Nov 17, 2026: Short sales 40.7%
- Nov 18, 2026: Short sales 68.3%
- Nov 19, 2026: Short sales 85.1%
- Nov 20, 2026: Short sales 48.3%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half. Shares held short, which are published twice a month, are not included here.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IBBiShares Biotechnology ETFWeight in the fund0.10%
- VSSVanguard Ftse All-World Ex-Us Small-Cap Index FundWeight in the fund0.04%
- SCZiShares MSCI EAFE Small-Cap ETFWeight in the fund0.02%
- VGKVanguard European Stock Index FundWeight in the fund0.01%
- IEURiShares Core MSCI Europe ETFWeight in the fund0.01%
- IEFAiShares Core MSCI EAFE ETFWeight in the fund0.00%
- VEAVanguard Developed Markets Index FundWeight in the fund0.00%
- AVDEAvantis International Equity ETFWeight in the fund0.00%
- SPDWState Street(R) SPDR(R) Portfolio Developed World ex-US ETFWeight in the fund0.00%
- IDEViShares Core MSCI International Developed Markets ETFWeight in the fund0.00%
13 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 93
- Q4 2025: Managers 91
- Q1 2026: Managers 92
- Q2 2026: Managers 77
Institutional investors by quarter
The fund managers holding LKFT, quarter by quarter, from Q2 2015 to Q2 2025, 41 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 77 managers held 32.06M shares, worth $960M. During the quarter 8 opened a position, 23 closed one, 26 added and 29 trimmed.
The largest holders, Q2 2026
- Gilead SciencesIn the quarter
- Tang Capital ManagementIn the quarter
- Madison Avenue PartnersIn the quarter+40%
- Prosight ManagementIn the quarter+32%
- EcoR1 CapitalIn the quarter
- Ameriprise FinancialIn the quarter-11%
- Greenlight / DME (Einhorn)In the quarter
- Renaissance TechnologiesIn the quarter+29%
- BlackRockIn the quarter+8.3%
- Point72 (Cohen)In the quarter-19%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Gilead Sciences | 16.71M | $500M | |
| Tang Capital Management | 3.79M | $114M | |
| Madison Avenue Partners | 3.45M | +40% | $103M |
| Prosight Management | 2.04M | +32% | $61M |
| EcoR1 Capital | 1.67M | $50M | |
| Ameriprise Financial | 1.27M | -11% | $38M |
| Greenlight / DME (Einhorn) | 482.7K | $14M | |
| Renaissance Technologies | 407.8K | +29% | $12M |
| BlackRock | 338.2K | +8.3% | $10M |
| Point72 (Cohen) | 269.8K | -19% | $8.1M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Lakefront Biotherapeutics's filings show?
Who buys and sells is one part of Lakefront Biotherapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have LKFT's insiders bought or sold?
From – to – Lakefront Biotherapeutics's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold LKFT?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Greenlight / DME (Einhorn)'s, worth $14M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.